IMVARIA

IMVARIA is advancing noninvasive AI biomarkers for better patient lives. We bring artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases.

IMVARIA serves Fibresolve -- the first AI diagnostic tool in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Fibresolve is an FDA Breakthrough Device and is authorized by the FDA to serve as an adjunctive, non-invasive diagnostic tool for patients with suspected ILD and IPF.

Beyond ILD and IPF, IMVARIA is developing AI biomarkers in multiple areas including oncology, pulmonology, immunology, and more.